- Login
- Register & Subscribe
- Language: EN FR DE
Wednesday 9 June 2010
Company: Pieris AG
Appointee: Laurent Audoly
Germany
Pieris AG, which is developing a platform based of high penetration lipocalins called Anticalins, has appointed Laurent Audoly as chief scientific officer.
Dr Audoly comes from Merck & Co where he had the title of Biologics Research Site Lead. He has experience developing both pharmaceutical and biologic products.
The company’s lead product, PRS-050, is one of several anti-Vascular Endothelial Growth Factor products used to treat solid tumours. However, the company’s preclinical studies indicate that it may have a superior efficacy and safety profile.
Copyright 2010 Evernow Publishing Ltd
Tuesday February 7 2012
Friday February 3 2012
Monday January 23 2012
Wednesday January 11 2012
Wednesday January 4 2012